A detailed history of Geode Capital Management, LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,001,744 shares of ATXS stock, worth $9.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,001,744
Previous 697,215 43.68%
Holding current value
$9.37 Million
Previous $5.35 Million 163.24%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$6.99 - $16.69 $2.13 Million - $5.08 Million
304,529 Added 43.68%
1,001,744 $14.1 Million
Q4 2023

Feb 13, 2024

BUY
$4.42 - $8.06 $876,782 - $1.6 Million
198,367 Added 39.77%
697,215 $5.35 Million
Q3 2023

Nov 13, 2023

BUY
$6.89 - $9.86 $212,694 - $304,378
30,870 Added 6.6%
498,848 $3.72 Million
Q2 2023

Aug 11, 2023

BUY
$8.33 - $13.72 $1.95 Million - $3.21 Million
234,142 Added 100.13%
467,978 $3.9 Million
Q1 2023

May 15, 2023

BUY
$11.2 - $15.79 $1.23 Million - $1.74 Million
110,143 Added 89.05%
233,836 $3.11 Million
Q4 2022

Feb 13, 2023

BUY
$7.44 - $14.89 $87,702 - $175,523
11,788 Added 10.53%
123,693 $1.84 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $10.34 $82,295 - $286,511
27,709 Added 32.91%
111,905 $1.01 Million
Q2 2022

Aug 12, 2022

BUY
$2.46 - $6.96 $14,978 - $42,379
6,089 Added 7.8%
84,196 $252,000
Q1 2022

May 13, 2022

BUY
$3.92 - $7.1 $51,324 - $92,960
13,093 Added 20.14%
78,107 $524,000
Q4 2021

Feb 11, 2022

BUY
$5.08 - $8.62 $22,778 - $38,652
4,484 Added 7.41%
65,014 $350,000
Q3 2021

Nov 12, 2021

BUY
$7.32 - $12.9 $443,079 - $780,837
60,530 New
60,530 $535,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $142M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.